TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer
Junko Tsuchida, Rongrong Wu, Masayuki Nagahashi, John M. L. Ebos, Takashi Ishikawa, Masafumi Shimoda, Toshifumi Wakai, Kazuaki Takabe
Springer Nature ·
2025-11-21
· DOI 10.1245/s10434-025-18764-x
The publisher did not provide an abstract — full text is available via the link below.
Junko Tsuchida, Rongrong Wu, Masayuki Nagahashi, John M. L. Ebos, Takashi Ishikawa, Masafumi Shimoda et al. TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer. // Annals of Surgical Oncology. – 2025. – DOI: 10.1245/s10434-025-18764-x. – URL: https://doi.org/10.1245/s10434-025-18764-x
Junko Tsuchida, Rongrong Wu, Masayuki Nagahashi, John M. L. Ebos, Takashi Ishikawa, Masafumi Shimoda, Toshifumi Wakai, & Kazuaki Takabe (2025). TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-025-18764-x
Junko Tsuchida, et al. “TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer.” Annals of Surgical Oncology, 2025. doi:10.1245/s10434-025-18764-x.
@article{Tsuchida2025,
title = {TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer},
author = {Tsuchida, Junko and Wu, Rongrong and Nagahashi, Masayuki and Ebos, John M. L. and Ishikawa, Takashi and Shimoda, Masafumi and Wakai, Toshifumi and Takabe, Kazuaki},
journal = {Annals of Surgical Oncology},
year = {2025},
doi = {10.1245/s10434-025-18764-x},
url = {https://doi.org/10.1245/s10434-025-18764-x}
}